A Phase 3 interventional study of Tocilizumab (TCZ) and Methotrexate (MTX) in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 155 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 71st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 718 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 85 in phase 3, and was the 164th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to current MTX therapy. Participants will initiate treatment with TCZ weekly or every 2 weeks along with MTX at a stable dose orally in an open-label manner for 24 weeks. Participants with a disease activity score based on 28 joints (DAS28) less than or equal to (\</=) 3.2 at Week 24, will be randomized to either continue receiving a stable dose of MTX or to switch to matching placebo up to Week 52. Participants without a DAS28 score \</=3.2 at Week 24, will continue the same treatment in a non-randomized open-label manner up to Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score \</=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
Drug: Tocilizumab (TCZ) · Drug: Methotrexate (MTX)
Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
Drug: Tocilizumab (TCZ) · Drug: Methotrexate (MTX)
Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
Drug: Tocilizumab (TCZ) · Drug: Placebo (PBO)
TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
Also known as: Actemra
MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
PBO matching to MTX will be administered orally.
Change From Week 24 in Disease Activity Score Based on 28 Joints (DAS28) Score at Week 40
The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Week 24, Week 40
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology (ACR20) Response
The ACR20 response at any time was defined as \>/=20% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per deciliter \[mg/dL\]).
Time frame: Weeks 24, 40, and 52
Percentage of Participants Achieving 50% Improvement in American College of Rheumatology (ACR50) Response
The ACR50 response at any time was defined as \>/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).
Time frame: Weeks 24, 40, and 52
Percentage of Participants Achieving 70% Improvement in American College of Rheumatology (ACR70) Response
The ACR70 response at any time was defined as \>/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).
Time frame: Weeks 24, 40, and 52
Percentage of Participants With >/=1.2 Points Increase (Worsening) From Week 24 in DAS28 Score at Week 40 and 52
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28- score could range from 0 to 10, where higher score represented higher disease activity.
Time frame: Week 24, 40, and 52
Percentage of Participants With DAS28 Score <2.6 (DAS28 Remission)
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity.
Time frame: Week 40, Week 52
Percentage of Participants With DAS28 Score </=3.2 (Low DAS28)
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28-ESR score could range from 0 to 10, where higher score represented higher disease activity.
Time frame: Week 40, Week 52
Change From Week 24 in Bone Erosion Score at Week 40 for Participants in the Magnetic Resonance Imaging (MRI) Substudy
Bones from the wrist regions (carpal bones, distal radius, distal ulna, and metacarpal bases) and the metacarpophalangeal (MCP) joints (metacarpal heads and phalangeal bases) were assessed for erosion via MRI and scored separately based on the proportion of eroded bone compared to the 'assessed bone volume' judged from all available images. Scoring ranged from 0 (no erosion) to 10 (91-100%). Results were summed, resulting in scores from 0 to 80 for the wrist region, 0 to 150 for the MCP joints, and 0 to 230 on aggregate. A negative value for change from Week 24 in bone erosion score indicated an improvement.
Time frame: Weeks 24, Week 40
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to TCZ
Percentage of participants with positive results for ATA against TCZ at Baseline and at any of the post-baseline assessment time-points was reported. Participants positive at any post-baseline time points were participants who had no positivity at baseline for the same assay.
Time frame: Baseline, Post-baseline (assessed at Weeks 12, 24, 36, 52 and at follow up [Week 60])
Mean TCZ Serum Concentration
Time frame: Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)
Mean Soluble Interleukin-6 (IL-6) Receptor Concentration
Time frame: Baseline, Weeks 12, 24, 36, 52 and follow up (Week 60)
| Milestone | Period 1: All Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) | Period 2: Non-Randomized Participants (TCZ + MTX) |
|---|---|---|---|---|
| Started | 718 | 0 | 0 | 0 |
| Completed | 602 | 0 | 0 | 0 |
| Not completed | 116 | 0 | 0 | 0 |
| Withdrew: Adverse event | 37 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 16 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 11 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 31 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Participant non-compliance | 3 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 3 | 0 | 0 | 0 |
| Withdrew: Other | 4 | 0 | 0 | 0 |
| Milestone | Period 1: All Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) | Period 2: Non-Randomized Participants (TCZ + MTX) |
|---|---|---|---|---|
| Started | 0 | 147 | 147 | 308 |
| Completed | 0 | 132 | 129 | 250 |
| Not completed | 0 | 15 | 18 | 58 |
| Withdrew: Adverse event | 0 | 4 | 5 | 21 |
| Withdrew: Serious hypersensitivity reaction | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 | 5 | 16 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 7 | 5 | 8 |
| Withdrew: Physician decision | 0 | 0 | 2 | 4 |
| Withdrew: Participant non-compliance | 0 | 1 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 24 | 2.13 ± 0.816 | 2.11 ± 0.822 |
| Change at Week 40 | 0.15 ± 1.127 | 0.48 ± 1.275 |
The ACR20 response at any time was defined as \>/=20% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per deciliter \[mg/dL\]).
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 24 | 91.2 ± 0.816 | 83.0 ± 0.822 |
| Week 40 | 78.9 ± 1.127 | 68.7 ± 1.275 |
| Week 52 | 74.1 | 65.3 |
The ACR50 response at any time was defined as \>/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 24 | 74.1 ± 0.816 | 63.3 ± 0.822 |
| Week 40 | 63.9 ± 1.127 | 50.3 ± 1.275 |
| Week 52 | 62.6 | 47.6 |
The ACR70 response at any time was defined as \>/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 24 | 45.6 ± 0.816 | 37.4 ± 0.822 |
| Week 40 | 42.2 ± 1.127 | 34.0 ± 1.275 |
| Week 52 | 48.3 | 36.7 |
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28- score could range from 0 to 10, where higher score represented higher disease activity.
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 40 | 21.1 ± 0.816 | 28.6 ± 0.822 |
| Week 52 | 26.5 ± 1.127 | 29.9 ± 1.275 |
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity.
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 40 | 59.2 ± 0.816 | 49.7 ± 0.822 |
| Week 52 | 55.1 ± 1.127 | 48.3 ± 1.275 |
The DAS28 was derived from assessments of ESR measured in mm/h, TJC28, SJC28, and Patient's global assessment of disease activity according to 100-mm VAS. DAS28 score was calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. DAS28-ESR score could range from 0 to 10, where higher score represented higher disease activity.
| percentage of participants | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 40 | 76.9 ± 0.816 | 63.3 ± 0.822 |
| Week 52 | 68.0 ± 1.127 | 62.6 ± 1.275 |
Bones from the wrist regions (carpal bones, distal radius, distal ulna, and metacarpal bases) and the metacarpophalangeal (MCP) joints (metacarpal heads and phalangeal bases) were assessed for erosion via MRI and scored separately based on the proportion of eroded bone compared to the 'assessed bone volume' judged from all available images. Scoring ranged from 0 (no erosion) to 10 (91-100%). Results were summed, resulting in scores from 0 to 80 for the wrist region, 0 to 150 for the MCP joints, and 0 to 230 on aggregate. A negative value for change from Week 24 in bone erosion score indicated an improvement.
| units on a scale | Period 2: Randomized Participants (TCZ + MTX) | Period 2: Randomized Participants (TCZ + PBO) |
|---|---|---|
| Week 24 | 10.66 ± 11.217 | 9.05 ± 7.926 |
| Change at Week 40 | -0.10 ± 0.844 | 0.17 ± 1.067 |
Percentage of participants with positive results for ATA against TCZ at Baseline and at any of the post-baseline assessment time-points was reported. Participants positive at any post-baseline time points were participants who had no positivity at baseline for the same assay.
| percentage of participants | Overall Study Population |
|---|---|
| Baseline | 1.8 |
| Post-baseline | 1.5 |
| micrograms per milliliter | Overall Study Population |
|---|---|
| Baseline | 0.01 ± 0.223 |
| Week 12 | 8.66 ± 10.590 |
| Week 24 | 23.38 ± 22.979 |
| Week 36 | 25.58 ± 23.133 |
| Week 52 | 16.46 ± 20.976 |
| Week 60 | 6.16 ± 15.768 |
| nanograms per milliliter | Overall Study Population |
|---|---|
| Baseline | 40.4 ± 18.14 |
| Week 12 | 366.4 ± 179.21 |
| Week 24 | 441.3 ± 190.78 |
| Week 36 | 468.9 ± 211.73 |
| Week 52 | 336.3 ± 267.20 |
| Week 60 | 166.8 ± 211.39 |
Collected over From Baseline up to Week 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall Study Population | — | 72/713 (10.1%) | 348/713 (48.8%) |
| Event | Overall Study Population |
|---|---|
| PneumoniaInfections and infestations | 10/713 |
| Myocardial infarctionCardiac disorders | 5/713 |
| Chest painGeneral disorders | 5/713 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/713 |
| CellulitisInfections and infestations | 3/713 |
| Arthritis infectiveInfections and infestations | 2/713 |
| DiverticulitisInfections and infestations | 2/713 |
| UrosepsisInfections and infestations | 2/713 |
| Angina unstableCardiac disorders | 2/713 |
| Atrial fibrillationCardiac disorders | 2/713 |
| Event | Overall Study Population |
|---|---|
| Alanine aminotransferase increasedInvestigations | 101/713 |
| Upper respiratory tract infectionInfections and infestations | 93/713 |
| Hepatic enzyme increasedInvestigations | 69/713 |
| Aspartate aminotransferase increasedInvestigations | 65/713 |
| Urinary tract infectionInfections and infestations | 54/713 |
| NauseaGastrointestinal disorders | 53/713 |
| Liver function test increasedInvestigations | 52/713 |
| SinusitisInfections and infestations | 40/713 |
Intent-to-treat (ITT) population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy assessment.
| Age, Continuous(years) | Overall Study Population |
|---|---|
| Mean | 55.8 ± 12.31 |
| Sex: Female, Male(Participants) | Overall Study Population |
|---|---|
| Female | 556 |
| Male | 155 |
Showing the first 100 of 155 sites. Choose a country and city above to see the rest.
Ran from Nov 2013 to primary completion in Oct 2016, 35 months.
Results were first posted in Dec 2017, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 35 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate